Study Finds Paxlovid Treatment Does Not Reduce Risk of Long COVID
University of California, San Francisco (UCSF)A team of researchers from UC San Francisco has found that Paxlovid (Nirmatrelvir-ritonavir) did not reduce the risk of developing long COVID for vaccinated, non-hospitalized individuals during their first COVID-19 infection.